A Phase 2 interventional study of Mirikizumab and Placebo in Ulcerative Colitis, sponsored by Eli Lilly and Company. Completed at 77 sites in 16 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-06-17.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing mirikizumab in Colitis, Ulcerative — 4 open to participants now, 5 under way, 2 of them phase 3. mirikizumab · Colitis, Ulcerative.
Among the 13 studies testing mirikizumab in Colitis, Ulcerative, this one is the 6th largest by enrollment, is the only one that started in 2015, is one of 2 in phase 2, and was the 1st registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →4 of the 13 studies testing mirikizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:
University Hospital Schleswig-Holstein · Sites in Germany
Ages 18–75
Eli Lilly and Company · Sites in United States, Austria, Belgium and 13 more countries
Ages 2–19
Specialty Networks Research. · Sites in United States
Ages 21+
Rubix LS · Sites in United States
Ages 60–99
By country, each count listing its studies:
mirikizumab: first FDA approval 2023 (OMVOH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2015.
This study's enrollment of 249 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 172 across the 13 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 13 have an industry lead sponsor. The 5 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
16 studies in Colitis, Ulcerative by Eli Lilly and Company: 5 open now, 7 under way, 3 of them phase 3. Of 8 finished, 7 (88%) have results posted.
Among the 16 studies in Colitis, Ulcerative by Eli Lilly and Company, this one is the 8th largest by enrollment, is the only one that started in 2015, is one of 8 in phase 2, and was the 1st registered.
Eli Lilly and Company’s Colitis, Ulcerative studies by the year they started, since 2015.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing mirikizumab in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 16 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to test the hypothesis that treatment with mirikizumab is superior to placebo in providing clinical benefit to participants with moderate to severe ulcerative colitis (UC). This study will also investigate how the body processes the drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
50 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period. Participants who do not have a clinical response may choose to participate in the unblinded study extension period.
Drug: Mirikizumab
200 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period. Participants who do not have a clinical response may choose to participate in the unblinded study extension period.
Drug: Mirikizumab
600 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period. Participants who do not have a clinical response may choose to participate in the unblinded study extension period.
Drug: Mirikizumab
Placebo administered every 4 weeks (Q4W) intravenously (IV) during the induction period.
Drug: Placebo
Induction mirikizumab responders were re-randomized: 200 mg mirikizumab administered subcutaneously (SC) Q4W during the maintenance period.
Drug: Mirikizumab
Induction mirikizumab responders were re-randomized: 200 mg mirikizumab administered subcutaneously (SC) once every 12 weeks (Q12W) during the maintenance period.
Drug: Mirikizumab
Induction placebo responders: Placebo administered subcutaneously (SC) Q4W during the maintenance period.
Drug: Placebo
Induction non-responders: 600 mg mirikizumab administered intravenously (IV) once every 4 weeks (Q4W) during the Extension Open-Label.
Drug: Mirikizumab
Induction non-responders: 1000 mg mirikizumab administered intravenously (IV) once every 4 weeks (Q4W) during the Extension Open-Label.
Drug: Mirikizumab
Extension Induction responders: 200 mg mirikizumab administered subcutaneously (SC) once every 4 weeks (Q4W) during the Extension Open-Label
Drug: Mirikizumab
Also known as: LY3074828
Induction Period: Percentage of Participants With Clinical Remission at Week 12
Clinical remission at week 12 is a defined as achieving a 9-pt Mayo subscore for rectal bleeding=0, stool frequency=0 or 1 with ≥ 1 point decrease from baseline, and endoscopy=0 or 1, excluding Physician's Global Assessment (PGA). * Stool Frequency Subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); * Rectal Bleeding Subscore, based on the participant's diary and scored from 0 (no blood) to 3 (blood only passed); * Endoscopy Subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration); * Physician's Global Assessment subscore, based on the physician's overall assessment, and scored from 0 (normal) to 3 (severe disease). The total score ranges from 0 to 9 points, with higher scores representing more severe disease.
Time frame: Week 12
Induction Period: Percentage of Participants With Clinical Response at Week 12
Clinical response at week 12 is defined as a decrease in the 9-point Mayo subscores (rectal bleeding, stool frequency and the endoscopic findings) inclusive of \>= 2 points and \>=35% from baseline with either a decrease of rectal bleeding subscore of \>=1 or rectal bleeding subscore of 0 or 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores: * Stool Frequency Subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); * Rectal Bleeding Subscore, based on the participant's diary and scored from 0 (no blood) to 3 (blood only passed); * Endoscopy Subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The total score ranges from 0 to 9 points, with higher scores representing more severe disease.
Time frame: Week 12
Induction Period: Percentage of Participants With Endoscopic Remission at Week 12
Endoscopic remission at week 12 is defined as achieving a Mayo endoscopic score of 0 at Week 12. Endoscopy Subscore is based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration); The total score ranges from 0 to 3 points, with higher scores representing more severe disease.
Time frame: Week 12
Maintenance Period: Percentage of Participants With Endoscopic Remission at Week 52
Endoscopic remission at week 52 is defined as achieving a Mayo endoscopic subscore of 0 at Week 52. Endoscopy Subscore is based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration); The total score ranges from 0 to 3 points, with higher scores representing more severe disease.
Time frame: Week 52
Induction Period: Change From Baseline to Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score
The IBDQ is a 32-item subject-completed questionnaire that measures 4 aspects of subjects' lives: symptoms directly related to the primary bowel disturbance, systemic symptoms, emotional function, and social function (Guyatt et al. 1989). Responses are graded on a 7-point. Likert scale in which 7 denotes "not a problem at all" and 1 denotes "a very severe problem." Scores range from 32 to 224; a higher score indicates a better quality of life. LS Mean was calculated using MMRM model for post-baseline measures: Variable = Baseline + Geographical Region + Prior Biologic Therapy Group (N) + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, Week 12
Induction Period: Change From Baseline to Week 12 in 36-Item Short Form Health Survey (SF-36)
SF-36 Health Status Survey is a generic, health-related scale assessing participant's quality of life on 8 domains: physical functioning, social functioning, bodily pain, vitality, mental health, role-physical, role-emotional and general health. Domain scores: general health (range: 5-25); physical functioning (range: 10-30); role-physical (range: 4-8); role-emotional (range: 3-15); social functioning (range: 2-10); bodily pain (range: 2-12); vitality (range: 4-20); mental health (range: 5-25). Each raw scale score was converted to a scale score ranging from 0-100 points, with higher values representing a better outcome \[(Raw score) - min{raw score}\] / (max {raw score} - min{raw score}) x 100\]. LS Mean was calculated using Mixed effect Model Repeat Measurement (MMRM) model for post-baseline measures: Variable = Baseline + Geographical Region + Prior Biologic Therapy Group (N) + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, Week 12
Induction Period: Change From Baseline to Week 12 in Patient's Global Impressions of Severity (PGI-S) Score
PGI-S is a 1-item subject-rated questionnaire designed to assess the subject's impression of their disease symptoms at baseline (Guy 1976; Yalcin and Bump 2003). Responses are graded on a 7-point scale in which a score of 1 indicates that the subject's symptom(s) are "normal," a score of 2 indicates that the subject feels "borderline ill," a score of 3 indicates that the subject feels "mildly ill," a score of 4 indicates that the subject(s) feel "moderately ill," and scores of 5, 6, and 7 indicate that the subject feels "markedly ill," "severely ill," and "extremely ill," respectively. LS Mean was calculated using MMRM model for post-baseline measures: Variable = Baseline + Geographical Region + Prior Biologic Therapy Group (N) + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, Week 12
Induction Period: Patient's Global Impressions of Improvement (PGI-I) Score at Week 12
PGI-I scale is a subject-rated instrument designed to assess the subject's impression of change in their symptom(s) (Guy 1976; Yalcin and Bump 2003). Responses are graded on a 7-point Likert scale in which a score of 1 indicates that the subject's symptom(s) is "very much better," a score of 4 indicates that the subject's symptom(s) has experienced "no change," and a score of 7 indicates that the subject's symptom(s) is "very much worse."
Time frame: Week 12
Pharmacokinetics (PK): Area Under the Concentration-Time Curve During Dosing Interval at Steady State (AUCss, Tau) of Mirikizumab
Pharmacokinetics (PK): Area Under the Concentration-Time Curve During Dosing Interval at Steady State (AUCss, tau) of Mirikizumab
Time frame: Induction Period: Day (D) 1, D15 ± 2d, D29 ± 2d, D43 ± 2d, D57 ± 2d, D78-85; Maintenance Period: D85-92,D113± 7d,D141± 7d,D169± 7d,D225 ±7d,D281 ±7d,D337 ±7d,D393± 7d,D448± 7d,D504± 7d,D560± 7d,D616± 7d,D672± 7d,D728± 7d,D784± 7d,D840± 7d
Induction Period: Percentage of Participants With Symptomatic Remission at Week 12
Symptomatic remission is defined as a stool frequency score of 0 or 1 and a rectal bleeding score of 0. * Stool Frequency Subscore is based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal). * Rectal Bleeding Subscore is based on the participant's diary and scored from 0 (no blood) to 3 (blood only passed). The total score ranges from 0 to 1 points, with higher scores representing more severe disease. The percentage of response is calculated by dividing number of participants in the specified category by number of participants with non-missing values multiplied by 100.
Time frame: Week 12
Maintenance Period: Percentage of Participants With Symptomatic Remission at Week 52
Symptomatic remission is defined as a stool frequency score of 0 or 1 and a rectal bleeding score of 0. * Stool Frequency Subscore , based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); * Rectal Bleeding Subscore , based on the participant's diary and scored from 0 (no blood) to 3 (blood only passed); * Endoscopy Subscore , based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration); * Physician's Global Assessment subscore, based on the physician's overall assessment, and scored from zero (normal) to 3 (severe disease). The total score ranges from 0 to 1 points, with higher scores representing more severe disease. The percentage of response is calculated by dividing number of participants in the specified category by number of participants with non-missing values multiplied by 100.
Time frame: Week 52
Induction Period: Percentage of Participants With Endoscopic Improvement at Week 12
Endoscopic Improvement defined as achieving an endoscopic findings subscore of 0 or 1. Endoscopy Subscore is based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The percentage of response is calculated by dividing number of participants in the specified category by number of participants with non-missing values multiplied by 100.
Time frame: Week 12
Maintenance Period: Percentage of Participants With Endoscopic Improvement at Week 52
Endoscopic Improvement defined as achieving an endoscopic findings subscore of 0 or 1. Endoscopy Subscore is based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The percentage of response is calculated by dividing number of participants in the specified category by number of participants with non-missing values multiplied by 100.
Time frame: Week 52
| Milestone | Induction: Placebo IV Q4W | Induction: 50 mg Mirikizumab IV Q4W | Induction: 200 mg Mirikizumab IV Q4W | Induction: 600 mg Mirikizumab IV Q4W | Maintenance: Placebo SC Q4W | Maintenance: 200 mg Mirikizumab SC Q4W | Maintenance: 200 mg Mirikizumab SC Q12W | Induction Extension: 600mg Mirikizumab IV Q4W | Induction Extension: 1000mg Mirikizumab IV Q4W | Maintenance Extension: 200mg Mirikizumab SC Q4W |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 63 | 63 | 62 | 61 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received at least one dose of study drug | 63 | 63 | 62 | 60 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 60 | 61 | 60 | 57 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 2 | 2 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Did not receive drug | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 3 | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Induction: Placebo IV Q4W | Induction: 50 mg Mirikizumab IV Q4W | Induction: 200 mg Mirikizumab IV Q4W | Induction: 600 mg Mirikizumab IV Q4W | Maintenance: Placebo SC Q4W | Maintenance: 200 mg Mirikizumab SC Q4W | Maintenance: 200 mg Mirikizumab SC Q12W | Induction Extension: 600mg Mirikizumab IV Q4W | Induction Extension: 1000mg Mirikizumab IV Q4W | Maintenance Extension: 200mg Mirikizumab SC Q4W |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 13 | 47 | 46 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 13 | 47 | 46 | 0 | 0 | 0 |
| Withdrew: Rolled over to study amap (nct03519945) | 0 | 0 | 0 | 0 | 7 | 41 | 39 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 4 | 2 | 4 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Reason not collected | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Milestone | Induction: Placebo IV Q4W | Induction: 50 mg Mirikizumab IV Q4W | Induction: 200 mg Mirikizumab IV Q4W | Induction: 600 mg Mirikizumab IV Q4W | Maintenance: Placebo SC Q4W | Maintenance: 200 mg Mirikizumab SC Q4W | Maintenance: 200 mg Mirikizumab SC Q12W | Induction Extension: 600mg Mirikizumab IV Q4W | Induction Extension: 1000mg Mirikizumab IV Q4W | Maintenance Extension: 200mg Mirikizumab SC Q4W |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32 | 96 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 30 | 84 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 12 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Reason not collected | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | Induction: Placebo IV Q4W | Induction: 50 mg Mirikizumab IV Q4W | Induction: 200 mg Mirikizumab IV Q4W | Induction: 600 mg Mirikizumab IV Q4W | Maintenance: Placebo SC Q4W | Maintenance: 200 mg Mirikizumab SC Q4W | Maintenance: 200 mg Mirikizumab SC Q12W | Induction Extension: 600mg Mirikizumab IV Q4W | Induction Extension: 1000mg Mirikizumab IV Q4W | Maintenance Extension: 200mg Mirikizumab SC Q4W |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 68 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 68 |
| Withdrew: Rolled over to study amap (nct03519945) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 57 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Non-responder | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Clinical remission at week 12 is a defined as achieving a 9-pt Mayo subscore for rectal bleeding=0, stool frequency=0 or 1 with ≥ 1 point decrease from baseline, and endoscopy=0 or 1, excluding Physician's Global Assessment (PGA). * Stool Frequency Subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); * Rectal Bleeding Subscore, based on the participant's diary and scored from 0 (no blood) to 3 (blood only passed); * Endoscopy Subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration); * Physician's Global Assessment subscore, based on the physician's overall assessment, and scored from 0 (normal) to 3 (severe disease). The total score ranges from 0 to 9 points, with higher scores representing more severe disease.
| percentage of participants | Placebo IV Q4W | 50 mg Mirikizumab IV Q4W | 200 mg Mirikizumab IV Q4W | 600 mg Mirikizumab IV Q4W |
|---|---|---|---|---|
| Induction Period: Percentage of Participants With Clinical Remission at Week 12 | 4.8 (0.0 to 10.0) | 15.9 (6.8 to 24.9) | 22.6 (12.2 to 33.0) | 11.5 (3.5 to 19.5) |
Clinical response at week 12 is defined as a decrease in the 9-point Mayo subscores (rectal bleeding, stool frequency and the endoscopic findings) inclusive of \>= 2 points and \>=35% from baseline with either a decrease of rectal bleeding subscore of \>=1 or rectal bleeding subscore of 0 or 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores: * Stool Frequency Subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); * Rectal Bleeding Subscore, based on the participant's diary and scored from 0 (no blood) to 3 (blood only passed); * Endoscopy Subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The total score ranges from 0 to 9 points, with higher scores representing more severe disease.
| percentage of participants | Placebo IV Q4W | 50 mg Mirikizumab IV Q4W | 200 mg Mirikizumab IV Q4W | 600 mg Mirikizumab IV Q4W |
|---|---|---|---|---|
| Induction Period: Percentage of Participants With Clinical Response at Week 12 | 20.6 (10.6 to 30.6) | 41.3 (29.1 to 53.4) | 59.7 (47.5 to 71.9) | 49.2 (36.6 to 61.7) |
Endoscopic remission at week 12 is defined as achieving a Mayo endoscopic score of 0 at Week 12. Endoscopy Subscore is based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration); The total score ranges from 0 to 3 points, with higher scores representing more severe disease.
| percentage of participants | Placebo IV Q4W | 50 mg Mirikizumab IV Q4W | 200 mg Mirikizumab IV Q4W | 600 mg Mirikizumab IV Q4W |
|---|---|---|---|---|
| Induction Period: Percentage of Participants With Endoscopic Remission at Week 12 | 1.6 (0.0 to 4.7) | 3.2 (0.0 to 7.5) | 3.2 (0.0 to 7.6) | 1.6 (0.0 to 4.8) |
Endoscopic remission at week 52 is defined as achieving a Mayo endoscopic subscore of 0 at Week 52. Endoscopy Subscore is based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration); The total score ranges from 0 to 3 points, with higher scores representing more severe disease.
| percentage of participants | Placebo SC Q4W | 200 mg Mirikizumab SC Q4W | 200 mg Mirikizumab SC Q12W |
|---|---|---|---|
| Maintenance Period: Percentage of Participants With Endoscopic Remission at Week 52 | 7.7 (0.0 to 22.2) | 14.9 (4.7 to 25.1) | 28.3 (15.2 to 41.3) |
The IBDQ is a 32-item subject-completed questionnaire that measures 4 aspects of subjects' lives: symptoms directly related to the primary bowel disturbance, systemic symptoms, emotional function, and social function (Guyatt et al. 1989). Responses are graded on a 7-point. Likert scale in which 7 denotes "not a problem at all" and 1 denotes "a very severe problem." Scores range from 32 to 224; a higher score indicates a better quality of life. LS Mean was calculated using MMRM model for post-baseline measures: Variable = Baseline + Geographical Region + Prior Biologic Therapy Group (N) + Treatment + Time + Treatment\*Time (Type III sum of squares).
| score on a scale | Placebo IV Q4W | 50 mg Mirikizumab IV Q4W | 200 mg Mirikizumab IV Q4W | 600 mg Mirikizumab IV Q4W |
|---|---|---|---|---|
| Induction Period: Change From Baseline to Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score | 22.3 ± 4.41 | 33.0 ± 4.52 | 42.8 ± 4.40 | 45.2 ± 4.54 |
SF-36 Health Status Survey is a generic, health-related scale assessing participant's quality of life on 8 domains: physical functioning, social functioning, bodily pain, vitality, mental health, role-physical, role-emotional and general health. Domain scores: general health (range: 5-25); physical functioning (range: 10-30); role-physical (range: 4-8); role-emotional (range: 3-15); social functioning (range: 2-10); bodily pain (range: 2-12); vitality (range: 4-20); mental health (range: 5-25). Each raw scale score was converted to a scale score ranging from 0-100 points, with higher values representing a better outcome \[(Raw score) - min{raw score}\] / (max {raw score} - min{raw score}) x 100\]. LS Mean was calculated using Mixed effect Model Repeat Measurement (MMRM) model for post-baseline measures: Variable = Baseline + Geographical Region + Prior Biologic Therapy Group (N) + Treatment + Time + Treatment\*Time (Type III sum of squares).
| score on a scale | Placebo IV Q4W | 50 mg Mirikizumab IV Q4W | 200 mg Mirikizumab IV Q4W | 600 mg Mirikizumab IV Q4W |
|---|---|---|---|---|
| Physical Component Score | 3.4 ± 0.83 | 6.2 ± 0.86 | 5.9 ± 0.83 | 6.9 ± 0.85 |
| Mental Component Score | 3.2 ± 1.22 | 4.5 ± 1.26 | 6.8 ± 1.20 | 8.8 ± 1.25 |
| Physical Functioning | 2.1 ± 0.76 | 3.7 ± 0.78 | 4.6 ± 0.74 | 6.2 ± 0.77 |
| Role-Physical | 4.5 ± 1.19 | 7.5 ± 1.22 | 7.2 ± 1.17 | 8.0 ± 1.22 |
| Bodily Pain | 3.7 ± 1.15 | 7.9 ± 1.18 | 8.9 ± 1.14 | 10.0 ± 1.18 |
| General Health | 3.1 ± 0.93 | 3.8 ± 0.96 | 4.3 ± 0.92 | 5.1 ± 0.96 |
| Vitality | 3.3 ± 1.25 | 6.5 ± 1.28 | 7.5 ± 1.23 | 9.7 ± 1.28 |
| Social Functioning | 6.5 ± 1.22 | 8.0 ± 1.26 | 9.4 ± 1.21 | 11.6 ± 1.26 |
| Role-Emotional | 3.0 ± 1.22 | 3.7 ± 1.26 | 5.5 ± 1.20 | 7.6 ± 1.25 |
| Mental Health | 1.9 ± 1.18 | 3.7 ± 1.22 | 6.4 ± 1.17 | 7.6 ± 1.21 |
PGI-S is a 1-item subject-rated questionnaire designed to assess the subject's impression of their disease symptoms at baseline (Guy 1976; Yalcin and Bump 2003). Responses are graded on a 7-point scale in which a score of 1 indicates that the subject's symptom(s) are "normal," a score of 2 indicates that the subject feels "borderline ill," a score of 3 indicates that the subject feels "mildly ill," a score of 4 indicates that the subject(s) feel "moderately ill," and scores of 5, 6, and 7 indicate that the subject feels "markedly ill," "severely ill," and "extremely ill," respectively. LS Mean was calculated using MMRM model for post-baseline measures: Variable = Baseline + Geographical Region + Prior Biologic Therapy Group (N) + Treatment + Time + Treatment\*Time (Type III sum of squares).
| score on a scale | Placebo IV Q4W | 50 mg Mirikizumab IV Q4W | 200 mg Mirikizumab IV Q4W | 600 mg Mirikizumab IV Q4W |
|---|---|---|---|---|
| Induction Period: Change From Baseline to Week 12 in Patient's Global Impressions of Severity (PGI-S) Score | -0.84 ± 0.19 | -1.43 ± 0.20 | -1.90 ± 0.18 | -1.74 ± 0.19 |
PGI-I scale is a subject-rated instrument designed to assess the subject's impression of change in their symptom(s) (Guy 1976; Yalcin and Bump 2003). Responses are graded on a 7-point Likert scale in which a score of 1 indicates that the subject's symptom(s) is "very much better," a score of 4 indicates that the subject's symptom(s) has experienced "no change," and a score of 7 indicates that the subject's symptom(s) is "very much worse."
| score on a scale | Placebo IV Q4W | 50 mg Mirikizumab IV Q4W | 200 mg Mirikizumab IV Q4W | 600 mg Mirikizumab IV Q4W |
|---|---|---|---|---|
| Induction Period: Patient's Global Impressions of Improvement (PGI-I) Score at Week 12 | 3.37 ± 1.46 | 2.69 ± 1.31 | 2.39 ± 0.99 | 2.53 ± 1.16 |
Pharmacokinetics (PK): Area Under the Concentration-Time Curve During Dosing Interval at Steady State (AUCss, tau) of Mirikizumab
| Microgram*hour/milligram(ug*hr/ml) | 50 mg Mirikizumab IV Q4W | 200 mg Mirikizumab IV Q4W | 600 mg Mirikizumab IV Q4W | 200 mg Mirikizumab SC Q4W | 200 mg Mirikizumab SC Q12W |
|---|---|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration-Time Curve During Dosing Interval at Steady State (AUCss, Tau) of Mirikizumab | 3330 ± 42.5 | 10100 ± 35.0 | 24900 ± 36.6 | 3700 ± 41.5 | 1270 ± 42.3 |
Symptomatic remission is defined as a stool frequency score of 0 or 1 and a rectal bleeding score of 0. * Stool Frequency Subscore is based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal). * Rectal Bleeding Subscore is based on the participant's diary and scored from 0 (no blood) to 3 (blood only passed). The total score ranges from 0 to 1 points, with higher scores representing more severe disease. The percentage of response is calculated by dividing number of participants in the specified category by number of participants with non-missing values multiplied by 100.
| percentage of participants | Placebo IV Q4W | 50 mg Mirikizumab IV Q4W | 200 mg Mirikizumab IV Q4W | 600 mg Mirikizumab IV Q4W |
|---|---|---|---|---|
| Induction Period: Percentage of Participants With Symptomatic Remission at Week 12 | 20.6 (10.6 to 30.6) | 36.5 (24.6 to 48.4) | 58.1 (45.8 to 70.3) | 45.9 (33.4 to 58.4) |
Symptomatic remission is defined as a stool frequency score of 0 or 1 and a rectal bleeding score of 0. * Stool Frequency Subscore , based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); * Rectal Bleeding Subscore , based on the participant's diary and scored from 0 (no blood) to 3 (blood only passed); * Endoscopy Subscore , based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration); * Physician's Global Assessment subscore, based on the physician's overall assessment, and scored from zero (normal) to 3 (severe disease). The total score ranges from 0 to 1 points, with higher scores representing more severe disease. The percentage of response is calculated by dividing number of participants in the specified category by number of participants with non-missing values multiplied by 100.
| Percentage of Participants | Placebo SC Q4W | 200 mg Mirikizumab SC Q4W | 200 mg Mirikizumab SC Q12W |
|---|---|---|---|
| Maintenance Period: Percentage of Participants With Symptomatic Remission at Week 52 | 53.8 (26.7 to 80.9) | 76.6 (64.5 to 88.7) | 65.2 (51.5 to 79.0) |
Endoscopic Improvement defined as achieving an endoscopic findings subscore of 0 or 1. Endoscopy Subscore is based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The percentage of response is calculated by dividing number of participants in the specified category by number of participants with non-missing values multiplied by 100.
| percentage of participants | Placebo IV Q4W | 50 mg Mirikizumab IV Q4W | 200 mg Mirikizumab IV Q4W | 600 mg Mirikizumab IV Q4W |
|---|---|---|---|---|
| Induction Period: Percentage of Participants With Endoscopic Improvement at Week 12 | 6.3 (0.3 to 12.4) | 23.8 (13.3 to 34.3) | 30.6 (19.2 to 42.1) | 13.1 (4.6 to 21.6) |
Endoscopic Improvement defined as achieving an endoscopic findings subscore of 0 or 1. Endoscopy Subscore is based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The percentage of response is calculated by dividing number of participants in the specified category by number of participants with non-missing values multiplied by 100.
| Percentage of Participants | Placebo SC Q4W | 200 mg Mirikizumab SC Q4W | 200 mg Mirikizumab SC Q12W |
|---|---|---|---|
| Maintenance Period: Percentage of Participants With Endoscopic Improvement at Week 52 | 15.4 (0.0 to 35.0) | 57.4 (43.3 to 71.6) | 47.8 (33.4 to 62.3) |
Collected over Up To 39 Months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Induction: Placebo IV Q4W | 0/63 (0%) | 2/63 (3.2%) | 18/63 (28.6%) |
| Induction: 50 mg Mirikizumab Administered Every 4 Weeks (Q4W) | 0/63 (0%) | 0/63 (0%) | 14/63 (22.2%) |
| Induction: 200 mg Mirikizumab IV Q4W | 0/62 (0%) | 2/62 (3.2%) | 8/62 (12.9%) |
| Induction: 600 mg Mirikizumab IV Q4W | 0/60 (0%) | 3/60 (5%) | 14/60 (23.3%) |
| Maintenance: Placebo SC Q4W | 0/13 (0%) | 2/13 (15.4%) | 11/13 (84.6%) |
| Maintenance: 200 mg Mirikizumab SC Q4W | 0/47 (0%) | 2/47 (4.3%) | 27/47 (57.4%) |
| Maintenance: 200 mg Mirikizumab SC Q12W | 0/46 (0%) | 1/46 (2.2%) | 30/46 (65.2%) |
| Induction Extension: 600mg Mirikizumab IV Q4W | 0/32 (0%) | 1/32 (3.1%) | 9/32 (28.1%) |
| Induction Extension:1000mg Mirikizumab IV Q4W | 0/96 (0%) | 5/96 (5.2%) | 8/96 (8.3%) |
| Maintenance Extension: 200mg Mirikizumab SC Q4W | 0/68 (0%) | 3/68 (4.4%) | 30/68 (44.1%) |
| Event | Induction: Placebo IV Q4W | Induction: 50 mg Mirikizumab Administered Every 4 Weeks (Q4W) | Induction: 200 mg Mirikizumab IV Q4W | Induction: 600 mg Mirikizumab IV Q4W | Maintenance: Placebo SC Q4W | Maintenance: 200 mg Mirikizumab SC Q4W | Maintenance: 200 mg Mirikizumab SC Q12W | Induction Extension: 600mg Mirikizumab IV Q4W | Induction Extension:1000mg Mirikizumab IV Q4W | Maintenance Extension: 200mg Mirikizumab SC Q4W |
|---|---|---|---|---|---|---|---|---|---|---|
| AppendicitisInfections and infestations | 0/63 | 0/63 | 0/62 | 0/60 | 1/13 | 0/47 | 0/46 | 0/32 | 0/96 | 0/68 |
| Streptococcal bacteraemiaInfections and infestations | 0/63 | 0/63 | 0/62 | 0/60 | 1/13 | 0/47 | 0/46 | 0/32 | 0/96 | 0/68 |
| Head injuryInjury, poisoning and procedural complications | 0/63 | 0/63 | 0/62 | 0/60 | 1/13 | 0/47 | 0/46 | 0/32 | 0/96 | 0/68 |
| Breast neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/63 | 0/63 | 0/62 | 0/60 | 0/13 | 0/47 | 0/46 | 1/32 | 0/96 | 0/68 |
| Colitis ulcerativeGastrointestinal disorders | 0/63 | 0/63 | 1/62 | 1/60 | 0/13 | 1/47 | 1/46 | 0/32 | 2/96 | 0/68 |
| Clostridium difficile infectionInfections and infestations | 0/63 | 0/63 | 0/62 | 0/60 | 0/13 | 1/47 | 0/46 | 0/32 | 0/96 | 0/68 |
| Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/63 | 0/63 | 0/62 | 0/60 | 0/13 | 0/47 | 0/46 | 0/32 | 2/96 | 0/68 |
| GastroenteritisInfections and infestations | 0/63 | 0/63 | 1/62 | 1/60 | 0/13 | 0/47 | 0/46 | 0/32 | 0/96 | 0/68 |
| Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/63 | 0/63 | 0/62 | 1/60 | 0/13 | 0/47 | 0/46 | 0/32 | 0/96 | 0/68 |
| Large intestine perforationGastrointestinal disorders | 1/63 | 0/63 | 0/62 | 0/60 | 0/13 | 0/47 | 0/46 | 0/32 | 0/96 | 0/68 |
| Event | Induction: Placebo IV Q4W | Induction: 50 mg Mirikizumab Administered Every 4 Weeks (Q4W) | Induction: 200 mg Mirikizumab IV Q4W | Induction: 600 mg Mirikizumab IV Q4W | Maintenance: Placebo SC Q4W | Maintenance: 200 mg Mirikizumab SC Q4W | Maintenance: 200 mg Mirikizumab SC Q12W | Induction Extension: 600mg Mirikizumab IV Q4W | Induction Extension:1000mg Mirikizumab IV Q4W | Maintenance Extension: 200mg Mirikizumab SC Q4W |
|---|---|---|---|---|---|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 6/63 | 2/63 | 1/62 | 1/60 | 7/13 | 4/47 | 7/46 | 0/32 | 0/96 | 7/68 |
| Upper respiratory tract infectionInfections and infestations | 0/63 | 0/63 | 0/62 | 0/60 | 3/13 | 5/47 | 3/46 | 0/32 | 0/96 | 6/68 |
| Back painMusculoskeletal and connective tissue disorders | 0/63 | 0/63 | 0/62 | 0/60 | 3/13 | 1/47 | 3/46 | 0/32 | 0/96 | 6/68 |
| NasopharyngitisInfections and infestations | 6/63 | 5/63 | 3/62 | 5/60 | 1/13 | 6/47 | 8/46 | 5/32 | 7/96 | 14/68 |
| Vaginal haemorrhageReproductive system and breast disorders | 0/27 | 0/25 | 0/25 | 0/22 | 1/5 | 0/20 | 0/24 | 0/12 | 0/33 | 0/25 |
| NauseaGastrointestinal disorders | 4/63 | 2/63 | 2/62 | 3/60 | 2/13 | 3/47 | 0/46 | 0/32 | 0/96 | 0/68 |
| FatigueGeneral disorders | 0/63 | 0/63 | 0/62 | 0/60 | 2/13 | 1/47 | 3/46 | 0/32 | 0/96 | 0/68 |
| Injection site painGeneral disorders | 0/63 | 0/63 | 0/62 | 0/60 | 2/13 | 3/47 | 2/46 | 0/32 | 0/96 | 0/68 |
| Herpes zosterInfections and infestations | 0/63 | 0/63 | 0/62 | 0/60 | 2/13 | 1/47 | 0/46 | 0/32 | 0/96 | 0/68 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/63 | 0/63 | 0/62 | 0/60 | 0/13 | 6/47 | 1/46 | 0/32 | 0/96 | 0/68 |
All randomized participants.
| Age, Continuous(years) | Induction: Placebo IV Q4W | Induction: 50 mg Mirikizumab IV Q4W | Induction: 200 mg Mirikizumab IV Q4W | Induction: 600 mg Mirikizumab IV Q4W | Total |
|---|---|---|---|---|---|
| Mean | 42.62 ± 13.47 | 41.83 ± 14.06 | 43.35 ± 14.75 | 42.44 ± 13.371 | 42.56 ± 13.85 |
| Sex: Female, Male(Participants) | Induction: Placebo IV Q4W | Induction: 50 mg Mirikizumab IV Q4W | Induction: 200 mg Mirikizumab IV Q4W | Induction: 600 mg Mirikizumab IV Q4W | Total |
|---|---|---|---|---|---|
| Female | 27 | 25 | 25 | 23 | 100 |
| Male | 36 | 38 | 37 | 38 | 149 |
| Ethnicity (NIH/OMB)(Participants) | Induction: Placebo IV Q4W | Induction: 50 mg Mirikizumab IV Q4W | Induction: 200 mg Mirikizumab IV Q4W | Induction: 600 mg Mirikizumab IV Q4W | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 3 | 2 | 2 | 7 |
| Not Hispanic or Latino | 60 | 58 | 59 | 54 | 231 |
| Unknown or Not Reported | 3 | 2 | 1 | 5 | 11 |
| Race (NIH/OMB)(Participants) | Induction: Placebo IV Q4W | Induction: 50 mg Mirikizumab IV Q4W | Induction: 200 mg Mirikizumab IV Q4W | Induction: 600 mg Mirikizumab IV Q4W | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 10 | 5 | 13 | 5 | 33 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 5 | 0 | 7 |
| White | 52 | 57 | 44 | 56 | 209 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Induction: Placebo IV Q4W | Induction: 50 mg Mirikizumab IV Q4W | Induction: 200 mg Mirikizumab IV Q4W | Induction: 600 mg Mirikizumab IV Q4W | Total |
|---|---|---|---|---|---|
| Hungary | 5 | 3 | 6 | 4 | 18 |
| Czechia | 1 | 0 | 0 | 1 | 2 |
| Japan | 8 | 5 | 13 | 5 | 31 |
| United Kingdom | 2 | 2 | 0 | 2 | 6 |
| Moldova | 5 | 7 | 5 | 7 | 24 |
| Canada | 2 | 1 | 0 | 3 | 6 |
| Netherlands | 1 | 4 | 4 | 2 | 11 |
| Belgium | 4 | 7 | 3 | 7 | 21 |
| Denmark | 0 | 0 | 0 | 1 | 1 |
| Poland | 15 | 14 | 12 | 8 | 49 |
| Georgia | 4 | 7 | 2 | 1 | 14 |
| Lithuania | 4 | 1 | 3 | 1 | 9 |
| Australia | 1 | 3 | 1 | 2 | 7 |
| United States | 11 | 9 | 13 | 17 | 50 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Dec 2015 to primary completion in Dec 2017, 24 months.
Results were first posted in May 2020, 2 years 5 months after primary completion. A results delay was requested in Nov 2018.
Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 24 months is below that.
Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirikizumab